Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417193 | 0.84 | — | — | |
| SCHEMBL17773000 | 0.82 | ALDH1A1 (0.43) | ALDH1A1CYP3A4MCL1SMN1; SMN2TSHR | |
| SCHEMBL5138597 | 0.77 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2TSHRMAPTKMT2A | |
| SCHEMBL6147435 | 0.76 | SMN1; SMN2 (0.48) | ALDH1A1SMN1; SMN2TSHRMAPTKDM4E | |
| SCHEMBL17859666 | 0.75 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2TSHRMAPTKMT2A | |
| SCHEMBL17859667 | 0.75 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2TSHRMAPTKMT2A | |
| SCHEMBL417209 | 0.75 | MCL1 (0.69) | ALDH1A1CYP3A4MCL1SMN1; SMN2MAPT | |
| SCHEMBL8060600 | 0.72 | TSHR (0.56) | ALDH1A1SMN1; SMN2TSHRMAPTKMT2A | |
| SCHEMBL252121 | 0.72 | TSHR (0.56) | ALDH1A1SMN1; SMN2TSHRMAPTKMT2A | |
| SCHEMBL3991887 | 0.72 | MCL1 (0.71) | ALDH1A1CYP3A4MCL1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | disclosed |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | disclosed |
| EP-3804725-A2 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | Rhode Island Hospital (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3220914-B1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2017-12-21 | — | — | US | disclosed |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | ALDH1A1 3359/4885CYP3A4 3843/4885MCL1 152/4885 |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | ALDH1A1 3359/4885CYP3A4 3843/4885MCL1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.